MRZM Stock - Marizyme, Inc.
Unlock GoAI Insights for MRZM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $645,810 | $233,485 | $210,279 | $197,136 | N/A |
| Gross Profit | $238,908 | $179,166 | $129,925 | $138,844 | N/A |
| Gross Margin | 37.0% | 76.7% | 61.8% | 70.4% | N/A |
| Operating Income | $-34,086,516 | $-12,973,796 | $-8,821,383 | $-5,799,603 | $-1,058,039 |
| Net Income | $-69,539,336 | $-38,165,870 | $-10,997,929 | $-5,845,053 | $-1,058,039 |
| Net Margin | -10767.8% | -16346.2% | -5230.2% | -2965.0% | N/A |
| EPS | $-1.53 | $-0.94 | $-0.31 | $-0.22 | $-0.05 |
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.
Visit WebsiteEarnings History & Surprises
MRZMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | — | — | — | — |
Q2 2025 | Jun 4, 2025 | — | — | — | — |
Q2 2025 | May 15, 2025 | — | — | — | — |
Q1 2025 | Mar 7, 2025 | — | — | — | — |
Q4 2024 | Nov 15, 2024 | — | — | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.03 | — | — |
Q2 2024 | May 28, 2024 | — | $-0.05 | — | — |
Q1 2024 | Mar 24, 2024 | — | $-0.15 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.71 | — | — |
Q3 2023 | Aug 18, 2023 | — | $-0.48 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.12 | — | — |
Q1 2023 | Mar 24, 2023 | — | $-0.02 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.10 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.23 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.20 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.15 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.07 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.08 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.10 | — | — |
Latest News
Frequently Asked Questions about MRZM
What is MRZM's current stock price?
What is the analyst price target for MRZM?
What sector is Marizyme, Inc. in?
What is MRZM's market cap?
Does MRZM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MRZM for comparison